Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Condition(s):Pancreatic Adenocarcinoma MetastaticLast Updated:August 27, 2020Terminated
Hide Studies Not Open or Pending
Condition(s):Pancreatic Adenocarcinoma MetastaticLast Updated:August 27, 2020Terminated
Condition(s):Pancreatic AdenocarcinomaLast Updated:March 12, 2024Active, not recruiting
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:May 21, 2019Unknown status
Condition(s):Pancreatic AdenocarcinomaLast Updated:February 25, 2021Completed
Condition(s):Pancreatic AdenocarcinomaLast Updated:November 8, 2021Completed
Condition(s):Metastatic Adenocarcinoma of the PancreasLast Updated:December 9, 2022Recruiting
Condition(s):Pancreatic AdenocarcinomaLast Updated:November 25, 2019Withdrawn
Condition(s):Metastatic Colorectal Cancer; Colorectal Adenocarcinoma; Pancreatic Adenocarcinoma; Metastatic Pancreatic CancerLast Updated:February 5, 2024Terminated
Condition(s):Pancreatic AdenocarcinomaLast Updated:September 15, 2010Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:April 17, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.